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To identify perceived barriers and facilitators for HAART adherence among people living
with HIV/AIDS in Southern Puerto Rico using a Social Ecological framework.
Patients and Methods
Individual in-depths interviews were conducted with 12 HIV patients with a history of
HAART non-adherence. Interviews were audio-taped and transcribed. Content analysis
was performed for each transcribed interview by three independent coders using a code-
book. Using Atlas TI, super-codes and families were generated to facilitate the categoriza-
tion tree as well as grounded analyses and density estimates
Results
Most participants reported a monthly income of $500 or less (n = 7), a high school education
level (n = 7), being unemployed (n = 9) and being recipients of government health insurance
(n = 11). Three out of six women reported living alone with their children andmost men informed
living with their parents or other relatives (n = 4). For the grounded analyses, the top four sub-
categories linked to high number of quotations were mental health barriers (G = 32) followed by
treatment regimen (G = 28), health system (G = 24) and interpersonal relations (G = 16). The
top four sub-categories linked to high number of codes are treatment regimen (D = 4), health
status perception (D = 3), interpersonal relations (D = 3) and health system (D = 3).
Conclusion
The results of this study suggest the interconnection of HIV treatment adherence barriers at
various system levels. Future studies on HIV treatment barriers should explore these inter-
actions and investigate the possible synergistic effect on non-adherent behavior
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Introduction
HIV/AIDS is a chronic condition that requires a complex lifelong treatment. The goal of the
Highly Active Anti-retroviral Treatment (HAART) is to achieve and maintain viral suppres-
sion, preserve immune function and stop HIV progression. A major complication of the
HAART is side effects, which go from diarrhea and nausea to skin rash, lipodisthrophy and
hyperglicemia among others [1]. Drug resistance is also a major concern. When a patient
misses doses, the virus can become resistant to the regimen and the condition is likely to prog-
ress to AIDS. Since the HAART regimen was first used in 1996, the morbidity and mortality
rates of people living with HIV/AIDS have decreased substantially, making HIV a chronic con-
dition [2]. Great efforts have been made to make HAART available to patients; however, opti-
mal HAART adherence is critical, but problematic [3, 4].
As of January 2014, in Puerto Rico (PR) there have been reported 45,788 HIV/AIDS cases
and 25,896 reported deaths of people living with HIV/AIDS (approximately PR population, 3.5
million habitants) [4]. A total of 19,896 people are living with HIV/AIDS in Puerto Rico and,
out of these, 58.5% have progressed to AIDS [5]. According to a report published by the Puerto
Rico Department of Health titled “Puerto Rico Unmet Needs 2012”, approximately 70.94% of
people living with HIV/AIDS in Puerto Rico (N = 13,748) received primary medical care dur-
ing the year 2010 [6]. On the other hand, the Ponce health region of Puerto Rico, a mostly
rural zone, is the third region with most HIV/AIDS cases (15% of cases, N = 6,923) when com-
pared to the San Juan (24% of cases) and Bayamon (18%) regions located in the metropolitan
area of northern Puerto Rico. In the Ponce region, however, the number of AIDS cases is signif-
icantly higher (84%, N = 5,858) when compared to the rest of the island [7]. While a number of
factors contribute to progression from HIV to AIDS in Puerto Rico and Ponce region (eg. late
HIV testing), poor medication adherence may account for many cases. For example, informal
discussions with health care providers and HIV case managers in Southern Puerto Rico suggest
that some patients, especially women, tend to miss their monthly routine and fail to pick up
their prescription refills. Also, patients from distant regions travel to the southern region of the
island for treatment to avoid being recognized as HIV positive patients and sometimes the dis-
tance prevents them from having timely access to their medication.
A meta-analysis conducted by Mills et al (2006) reported significantly lower adherence rates
in North America (55%; 95% CI, 49% -62%) when compared with Sub-Sahara Africa (77%;
95% CI, 68% -85%) [6]. Various bio-psychosocial factors have been associated with poor medi-
cation adherence: complex drug regimen, side effects, perceived stigma, depression, self-effi-
cacy, social support and a negative social context [8–18] (i.e. poverty-associated conditions
[9]). For example, Dilorio et al (2009) tested a psychological model to explain HAART adher-
ence and found that medication-taking behaviors are affected by the interaction of self-efficacy,
depression, stigma, patient satisfaction and social support, all potentially modifiable variables
[15]. However, Penn, Watermeyer and Evan (2011) concluded that even though some barriers
in HAART adherence seem to be universal, others may be culturally specific such as the socio-
cultural (i.e. myths and rumors), economic (i.e. poor financial security) and systemic factors
(i.e. poor communication between hospital and clinics) [11]. Former models of medication
adherence have focused on patient level barriers, however, the field is moving forward with
more systemic models in order to gain a more comprehensive understanding of this problem
[19].
The purpose of this study was to identify perceived barriers and facilitators for HAART
adherence among people living with HIV/AIDS in Southern Puerto Rico. The data presented
in this article is part of a three-phase, mixed method study aimed at determining predictors of
HAART non-adherence in Puerto Rican people living with HIV.
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Material and Methods
Study design
We used qualitative methods (key informant interviews) and a social ecological framework to
gain in-depth understanding of perceived system barriers (i.e. individual, micro-system, meso-
system, exo-system, macro-system and crono-system.) associated with HAART adherence.
The purpose was to focus on the phenomenological aspect of voluntarily missing doses in the
context of a systemic socio-ecological perspective. Thus, instead of the quantification of medi-
cation adherence we inquired about the subject’s perceived experience regardless of time and
frequency. Findings will report on the development of a HAART model of adherence and
future interventions to reduce HIV/AIDS disparities in Puerto Rico.
Ethic Statement
Ethical approval was granted by the Ponce School of Medicine and Health Science (protocol
number 120522-EC) and the University of Puerto Rico, Medical Science Campus (protocol
number A8160112). Prior to the interview, the study was explained to the participant and an
opportunity to ask questions was provided. Written informed consent was obtained from each
participant. Confidentiality was kept by using a study identification number, rather than sub-
jects' names. During the interviews, participants were asked to change their name in order to
minimize risk of identification, however, all of them decided not to mention their name during
the interviews. Since there were no names recorded during the in-depth interviews subjects
were identified as “participant #1”, “participant # 2”, etc. Data was kept in a locked filing cabi-
net and was available only to the researcher.
Study sample
Amixed purposeful sampling method was employed (stratified and criterion) in order to facili-
tate data triangulation [20]. Participants were stratified by gender (6 women and 6 men) and
risk group (injection drug user (n = 4), men who have sex with men (n = 4), heterosexual
(n = 4)). Considering the phenomenological nature of the study, the recruited sample size pro-
vided enough data to reach a descriptive saturation. The inclusion criteria were: 1) 21 years of
age and older, 2) receiving HAART treatment at the time of the study, 3) a history of HAART
non-adherence for at least one month as reported by the health care provider or case manager
based on clinical record notes and, 4) willing to provide voluntary consent. Participants were
recruited from clinics and community and government based organizations (C/GBO) that pro-
vide health services to patients living with HIV/AIDS in the southern region of Puerto Rico.
Before beginning the recruitment process, the principal investigator met with the clinic admin-
istrators, health care providers and case managers to discuss the study objectives, inclusion/
exclusion criteria and to design a recruitment process. Case managers and health care providers
who invited patients to participate in the study identified potential participants. The principal
investigator discussed the informed consent and conducted all the interviews.
Interview guide
The principal investigator and three members of the research team, with expertise in qualitative
research design, developed the interview guide (Fig 1). Questions were designed following the
research question and the framework of the Social Ecological Model and techniques proposed
by Kvale (1996) [21] (e.g. introducing questions, probes, etc.). The interview guide was pilot-
tested with two adult HIV patients for clarity and relevance of the questions, which resulted in
slight modifications of some of the questions and the addition of prompts. Questions were
Barriers and Facilitators for HIV Treatment Adherence in Puerto Ricans
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Fig 1. Interview guide (Prompt questions not included).
doi:10.1371/journal.pone.0125582.g001
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open ended in order to facilitate participants’ insightful response and prompts were used to
assist in focused elaboration and depth in participants’ responses. Questions addressed patient-
perceived barriers and facilitators of HAART adherence at various systems’ levels (e.i. individ-
ual, micro-system, meso-system, etc.).
Data Collection
Face-to-face in-depth interviews were conducted using an open-ended question guide to ask
about the barriers for HAART non-adherence at different system levels (individual, micro-sys-
tem, meso-system, etc.). It also inquired about the facilitators to HIV treatment adherence in
order to identify opportunities for interventions. This process took approximately 40 minutes.
A $15 stipend was provided to participants to compensate for their time and effort. The inter-
views were audio-recorded, transcribed by a research assistant for analysis and translated into
English for publication purposes.
Data Analysis
Transcribed interviews were analyzed using a combination of hand coding and Atlas TI (Hap-
berg, Germany), a software program designed to facilitate the analysis of qualitative data. Con-
tent analysis was performed for each transcribed interview by three independent coders (the
principal investigator and two trained research assistants) as a form of investigator triangula-
tion. An initial list of themes was identified and coded by the principal investigator, a process
guided by the theoretical framework described above. A codebook was developed to further
define and operationalize each of the themes. New themes and concepts were added to the
codebook as they emerged from the transcripts. Two additional members of the research team
with expertise in qualitative data analysis coded each transcript independently, coders subse-
quently met to discuss codes and categories and to further establish the inter-coder agreement.
In other words, after all members finished coding the transcript, they met to compare their
analysis and discuss discrepancies. Disagreements were discussed until consensus was reached.
Using Atlas TI, super-codes and families were generated to facilitate the categorization tree.
Categories and sub-categories (i.e. Micro-system level barriers and peer influence, etc.) were
derived from initial codes. Grounded analyses and density estimates were also performed.
Grounded analysis (G) is the number of quotations assigned to each code. Density (D) is the
number of codes assigned to each category.
Results
Twelve in-depth interviews were conducted with HIV/AIDS patients who voluntarily missed
medication doses at any time during the course of their treatment (6 women and 6 men). Par-
ticipants’ characteristics are summarized in Table 1. Mean age was 40.5 (SD = 11.41) for
women and 39.5 (SD = 5.54) for men. Most participants reported a monthly income of $500 or
less (n = 8), a high school education level (n = 6), being unemployed (n = 9) and being recipi-
ents of government health insurance (n = 11). Three out of six women reported living alone
with their children and most men informed living with their parents or other relatives (n = 4).
On the other hand, the qualitative analysis of transcripts summarized in Fig 2 revealed seven
category themes corresponding to various system level barriers to HAART adherence as well as
facilitators.
Grounded (G) and density analyses (D) for HAART adherence barriers and facilitators are
summarized in Table 2. For the grounded analyses, the top four sub-categories linked to high
number of quotations were mental health barriers (G = 32) followed by treatment regimen
(G = 28), health system (G = 24) and interpersonal relations (G = 15). The top four sub-
Barriers and Facilitators for HIV Treatment Adherence in Puerto Ricans
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categories linked to high number of codes are treatment regimen (D = 4), health status percep-
tion (D = 3), interpersonal relations (D = 3) and health system (D = 3).
Patients’ perception of level barriers for HAART adherence
Patient level HAART adherence barriers were those related to the participant’s personal char-
acteristics, emotions, behaviors and perceptions. When participants were asked about how
their thoughts, feeling or personal characteristics might have prevented them in the past from
taking the HAART medication, they described a list of factors summarized in these categories:
treatment regimen, mental health issues and health status perception. A total of 69 quotations
(grounded analysis) and 9 codes (density analysis) were linked to the patient level category. As
expected, medication side effects, a treatment regimen sub-category, emerged as an adherence
barrier. The following verbatim depict the anticipatory belief that medication side effects will
make the participant sick, associating emesis as a medication side effect to a sick status.
Participant 8: “So that's why I stopped taking them [the HAART medication]. Because, I'll be
honest, yesterday they changed my meds and today I had breakfast and had that in my mind,
and I said I'm going to take them, I'm going to take them but then I have also in mind that I
will become ill, throwing up and those other things”
This participant, on the other hand, stopped taking the HAART medication after a consid-
erate weight gain:
Table 1. Participants’ characteristics.
Variable Frequency (%)
Sex Male 6 (50%)
Female 6 (50%)
Living with Spouse/partner 3 (25%)
Parents (or one of them) 3 (25%)
Siblings 3 (25%)
Other family members 2 (16.7%)
Alone 1 (8.3%)
Vocational status Employed (either part or full time) 2 (16.7%)
unemployed 9 (75%)
Student 1 (8.3%)
Academic history Middle school 4 (33.3%)
High School 6 (50%)
Technical/Associate degree 2 (16.7%)
Civil status Never married 5 (41.7%)
Living together (not married) 3 (25.0%)
Married but living separate 1 (8.3%)
Divorced 2 (16.7%)
Widow 1 (8.3%)
Sexual preference Same sex 3 (25%)
Opposite sex 8 (66.7%)
Both sexes 1 (8.3%)
Monthly Income $500 or less 8 (66.7%)
$501 to $999 3 (25%)
$1,000 to 1,500 1 (8.3%)
doi:10.1371/journal.pone.0125582.t001
Barriers and Facilitators for HIV Treatment Adherence in Puerto Ricans
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Fig 2. Emergent themes by category.
doi:10.1371/journal.pone.0125582.g002
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Participant 11: “I ate a lot and became very fat.Wow, I used to weight 140 pounds. I have
never weighed that much. I said, Oh, no, this can’t be and I stopped taking the [HAART]
medication.”
Another expected theme found was the interaction between mental health issues and
HAART medication adherence. Various patients, such as the one below, talked about
depression:
Participant 12:“Ah, sometimes when I’m depressed I don’t take them [HAART medication].”
Other patients talked about the interference of addictive behavior with HAART non-
adherence:
Participant 4: “When you are part of the “drug” environment, you become irresponsible for
your health, irresponsible with others, and even irresponsible with the doctor’s appointments
and all the costs.”
Participant 8: “When I drink [alcohol] then, I don’t mix the [HAART] pills because that is not
good,mixing the two things”
Surprisingly, some participants attributed good and bad health status perception to medica-
tion non-adherence. The following verbatim was from a patient who had not taken her medica-
tion for 20 years and this is what encouraged her non-adherence:
Participant 10:“Nothing, I didn’t get sick, not even a cold. I knew I was HIV positive but, the
first thing that came to my mind was that I didn’t have anything.”
Table 2. Grounded and density analyses of HAART adherence barriers and facilitators.
HAART Adherence Barriers Grounded (G) Density (D)
Patient level (G = 69; D = 9) Treatment regimen 28 4
Mental health 32 2
Health Status perception 9 3
Micro-system level (G = 21; D = 4) Interpersonal relations 15 3
Health literacy 5 1
Meso-system level (G = 19; D = 5) Environment related 8 1
Health care organization 2 1
Illegal medication selling 5 1
Alternative therapy use 2 1
Financial hardship 2 1
Exo-system level (G = 33; D = 4) Health System 24 3
Transportation 9 1
Macro-system barriers (G = 12; D = 1) Stigma & discrimination 12 1
HAART Adherence Facilitators Grounded (G) Density (D)
Patient level (G = 18; D = 3) Desire to live 4 1
Spiritual practice/beliefs 4 1
Concern about health status 10 1
Micro-system level (G = 25; D = 3) Social support (family/friends and clinical personnel) 18 2
Desire to take care of children 7 1
doi:10.1371/journal.pone.0125582.t002
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Another participant narrated how every time she took the HAART medication regimen she
felt her health was deteriorating.
Participant 8:“Sometimes negative thoughts come to my mind and I say- why I am going to
keep taking the medication if I am falling behind [not getting well]”
Patients’ perception of micro-system barriers for HAART adherence
Micro-system level barriers are those factors related to interpersonal face-to-face relationships
manifested in different contexts. Grounded value for this category is 69 and density value was
4. The subcategories that emerged under this theme are barriers related to interpersonal rela-
tions and health literacy.
A female patient explains how feeling alone due to lack of social support was a catalyst for
not taking her medication.
Participant 11: “Well, it always affected me because I was always alone.My mother was never
with me and my father neither. I don’t know, I always felt alone like I didn’t matter to
anyone. . .”
An injection drug user shares his experience about how peers influenced his decision not to
take the HAART medication.
Participant 3: [peers to participant] “Are you going to waste time looking for that [meds]?. Is
like, any way we were using drugs that [medication] is not going to have any effect. . .I listened
to them and let myself [influence] by what they said”
Patients’ perception of meso-system barriers for HAART adherence
Meso-systems are the interaction of two micro-systems containing the subject. In order to
identify these interactions, participants were asked how their social environments might have
influenced their non-adherent behavior. They identified the following barriers: environment
related, health care organization, illegal medication selling, alternative therapy and economic
hardship. Grounded value for this category is 19 and density value was 5.
This female patient shares her experience of the first time she was sentenced to serve time in
jail for a crime she committed. She talks about how being in jail and away from her children
was the precipitating factors for becoming depressed and not taking the HAART medication.
Participant 6: “Look, I was an inmate; I got out of jail six or seven months ago. Inside there I
was depressed; first time in my life [in jail] and I fell behind and behind. . .I was given the
medications and the doctor and the nurse would tell me to take them and I faked it; after-
wards I took them out of my mouth. . .I waited until I was outside or another place and I took
them out and hid them. I didn’t drink them. Sometimes I had a lot of little [pill] envelopes and
I was like “oh my God, wait a minute, if they come to do an inspection or something and they
inspect the cell they will find it. I would take them and throw them out.”
Surprisingly, two participants mentioned HAART medication being sold in the illegal street
market.
Barriers and Facilitators for HIV Treatment Adherence in Puerto Ricans
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Participant 12: They sell them.
Interviewer: They sell the medications? Do they have clients to sell them to?
Participant 12: They sell them for. . .for drugs. . .
Interviewer: And who would buy the medication?
Participant 12: “Los de los puntos” (Drug Lords)
Patients’ perception of exo-system barriers for HAART adherence
Exo-system barriers are those taking place between two or more contexts, at least one of which
does not contains the patient. For example, exo-system level health system barriers emerging
from patients’ narratives included the health system, particularly medication access, distrust
and co-payment rates. Transportation was another common barrier identified. Grounded
value for this category is 33 and density value is 4.
Sometimes the bureaucratic health system procedures and regulations make it difficult to
provide medication on time. The following quote came from a patient, beneficiary of the gov-
ernment health insurance plan, who had to wait for the medication to be approved.
Patient 3: “But what happens now is that they are taking two or three months to approve
some medications, already the treatment is being interrupted abruptly. That is what is
happening.”
Some participants stated that there are times when the HAART medication is no available
in the pharmacies.
Participant 1: “I needed another medication. I need to look for it because last month it wasn’t
available.”
Participant 8: “Well, we were without medication, I mean, usually they solve it quickly but,
sometimes we are two or three days without taking the medicine.”
Patients’ perception of macro-system barriers for HAART adherence
Macro-system barriers are those patterns embedded in the culture or subculture and mani-
fested in a continuum of micro-meso-exo systems. As expected, real and perceived stigma and
discrimination was the only macro-system barrier identified in the narratives. Some partici-
pants talked about their experience of being branded and rejected and others described the
experience of other fellow patients. Grounded value for this category is 12 and density value is
1.
A woman reported her experience of being rejected by family members and neighbors, after
they found out she was HIV positive. She felt ashamed and traumatized with the experience.
Participant 10: “. . .everybody found out, and everybody looked at me like
“look, she has AIDS, don’t go near her, so on”, and that
Barriers and Facilitators for HIV Treatment Adherence in Puerto Ricans
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traumatized me even more and that’s why I was in denial with the
pills. . .”
Sometimes, fear of being rejected might complicate the medication-taking routine and
doses may be missed. This woman described how difficult it was to keep up with the medica-
tion schedule when she was at work.
Participant 8: “I couldn’t take them [the pills] because my boss and the co-workers were
around. Other times I would have to hide but, I would take the pills hours later [after the indi-
cated hour].
Another participant shared the story of a friend who was HIV positive and was rejected by
member of the community. Apparently, after the neighbors found out he was HIV positive
they yelled at him and mocked him. He then refused to take the HAART medication.
Participant 4: “My friend, he is constantly yelled at by the neighbors. [the participant tells
him] go to the clinic [to continue with the HIV treatment] and he says. . .ah, not anymore.”
HAART adherence facilitators
Participants were asked about the factors or situations that helped them resume their HAART
regimen. The identified facilitators were grouped around a multi-level ecological perspective.
Their responses were categorized under patient level facilitators and micro-system level facili-
tators. The majority of the quotes fell under the micro-level facilitators (G = 25). Surprisingly,
concerns about health status were the most quoted code (G = 10) under participant level facili-
tators, when compared to other factors at the patient level (desire to live, G = 4; spiritual
beliefs/practices, G = 4). Grounded value for this category is 25 and density value is 3.
Desire to live, spiritual practices and beliefs along with participants’ concerns about poor
health status were the patient levels facilitators identified. To our surprise, some participants
waited until their viral load was high, and opportunistic conditions developed, to take their
HAART medication.
Patient level facilitators. Patient level facilitators include the individual’s desire to live
(G = 4), spiritual practices (G = 4) and concerns about health status (G = 10). The most quoted
facilitator by participants was concern with health status. In other words, once patients experi-
enced physical symptoms as a consequence of viral replication due to non-adherence, they
became worried about their health or even scared and started taking their medication. The fol-
lowing participant described his health condition when he returned to the clinic after a long
period without taking his medication. He was so deteriorated that the doctor told him he
might not survive.
Participant 13: “When I returned here [the HIV clinic] I looked liked Jesus Christ in the cross,
so skinny that my ribs would show off.Here [the HIV clinic] they raised me up again”
Some participants take long breaks from taking the medication and start the regimen again
once they feel their health is starting to deteriorate.
Participant 12: “I felt weak. . .sometimes when I stop taking them I feel like, Oh my God, so
tired and then I realize I have to start taking them again.”
Barriers and Facilitators for HIV Treatment Adherence in Puerto Ricans
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Micro-system level facilitators. As expected, social support emerged as the most cited
form of HAART adherence facilitator. According to participants, family, friends, neighbors,
clinicians and case managers among others provided support. Another facilitator, mostly
quoted by females, was the desire to become healthy again so they can take care of their chil-
dren. The following quote depicts this facilitator:
Participant 11: “My children; I’m constantly thinking about them. I have two children; they
are very healthy and they are the reason why I exist.”
Primary health care experience
The purpose of exploring this area was to inquire about participants’ barriers for not following
up on primary health care (PHC) recommendations. We first asked about the clinical recom-
mendations provided by their physicians and then queried them about challenges related to
follow up recommendations. Recommendations ranged from HAART medication adherence
to those related to healthy diet and exercise. Other recommendations were routine clinical lab-
oratory tests and referrals to other health care professionals. For a complete list of recommen-
dation codes refer to Fig 2. In general, most participants said they followed the PHC
recommendations. However, some reported barriers for not following these recommendations.
The identified barriers fell under the patient level and the exo-system level.
Patient level barriers for PHC recommendations. Patient level barriers for PHC recom-
mendation adherence were fear or shame about clinical procedures and substance abuse. For
example, one male participant was afraid of dental procedures and another female participant
felt ashamed about gynecological procedures.
Participant 1: “The PAP test is difficult, I feel ashamed. It’s been a lot of years [without per-
forming a PAP smear test]
Participant 4: “It’s difficult [to follow the recommendation referral to] the dentist because I’m
afraid. . .”
Exo-system level barrier for PHC recommendations
The only exo-system barriers to PHC recommendation adherence were related to transpor-
tation limitations. The following quote emphasized the problem.
Participant 10:What prevents me from following the [laboratory] tests is the [problem with]
transportation.Where I live is not near. . .you have to walk a lot. . .”
Discussion
The purpose of this study was to identify perceived HAART adherence barriers and facilitators
in a sample of HIV patients with a history non-adherent behavior. The study was framed
under a social ecological framework; an approach that facilitates the understanding of medica-
tion adherence behavior by studying the interaction of socio-ecological systems: individual,
micro-system, meso-system, exo-system, macro-system and crono-system [19]. A total of
twelve HIV patients (6 women and 6 men) participated in the study providing an interesting
range of responses. The social ecological perspective framework was used for the guided
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interviews and the emergent categories falling under these system level categories: patient level
barriers, micro-system level, meso-system level, exo-system level and macro-system level.
Table 3 summarizes key findings and implications.
Some of the emergent barriers have been widely cited in the literature; among these are
medication side effects [22], treatment regimen [23], depression [24], transportation, stigma
[25], and drug addiction [26]. Other barriers have been less studied, for example, peer influ-
ence, a good or bad health status perception, and illegal medication selling [9]. For example,
medication side effects and treatment regimen (e.g. inconvenient scheduling), among other
factors, may lead to treatment fatigue and subsequent non-adherence; yet, this phenomenon is
not widely addressed [27]. Studies on medication side effects and regimen as proxies for
HAART treatment fatigue and adherence, and opportunities for interventions are warranted.
Depression is a very common barrier identified in the literature. As such, Gonzalez et. al. con-
ducted a study looking at the psychosocial and cultural factor associated with depression in a
sample Hispanic men diagnosed with HIV [28]. The investigators identified several correlates
of depression such as stress, self-esteem, substance abuse and physical violence, and recom-
mended further research to determine how interactions of these variables impact medication
adherence. Regarding perception of health status, Cardarelli and collaborators found that HIV
patients (including Hispanics) when rating their general health as fair/poor were 4 times more
likely to be non-adherent to HAART (odds ratio [OR], 4.34; 95% confidence interval [CI],
1.19–15.79) [29].
HIV treatment non-adherence has been studied widely [8] and efforts are currently concen-
trated in the creation and implementation of interventions to promote adherence [30],
Table 3. Key Findings and implications for HAART adherence barriers and facilitators.
Key Findings Implications
1. Patient level medication adherence barriers
were the most commonly cited (G = 69)
challenge.
a) Studies looking at the interactions of these barriers
with the adherence behavior of Puerto Rican patients
are warranted.
2. Within the patient level barriers, mental health
factors are still very prevalent.
b) Mental health, particularly depression and
addictions, is a common barrier identiﬁed in the
literature.
c) Screening efforts should be reinforced.
3. Exo-system level barriers are the second most
cited category (G = 33)
d) Unfolding the role of health system barriers in
HAART adherence will shed light to challenges beyond
patients’ control.
e) Future studies should include perspectives of actors
representing different areas of the health system (e.g.
health care providers, administrators, case managers,
etc.).
4. Within the exo-system level barriers, those
related to the health system were more common.
f) Health system barriers are usually beyond the
patients’ control.
5. Medication adherence facilitators fell into two
categories: patient level and micro-system level.
g) Comprehensive studies on adherence facilitators
should inquire about other system level factors (e.g.
meso-system, exo-system, etc.).
6. Social support remains a common medication
adherence facilitator
h) Social support is a facilitator widely studied in the
literature. Intervention efforts should consider this
facilitator.
7. Concerns about health status, particularly
health deterioration, was the second most
common medication adherence facilitator
i) This facilitator may be a dangerous one, particularly
if patients wait until their health is deteriorated to start
taking their medication.
8. HAART adherence is a complex challenge
engaging multi-level systems.
j) Studying multiple systems’ levels of barriers to HIV
treatment adherence can better guide the development
of more comprehensive interventions.
doi:10.1371/journal.pone.0125582.t003
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including the incorporation of technology-assisted interventions [31]. The field has moved for-
ward significantly but, in order to maximize these efforts and become more efficient, it is
imperative to incorporate a systemic approach for a more comprehensive understanding of the
phenomenon and, thus, develop more effective intervention [19].
Our findings suggest that HAART medication non-adherence is a complex problem engag-
ing multi-level system factors into the equation. For example, patient level barriers manifest
and interact with other systems as in the case of patients with depression (patient level)
encountering stigmatizing discrimination (exo-system) and lack of social support (micro-sys-
tem), sinking deeper into depression, thus, engaging in HAART treatment non-adherent
behavior. Another hypothetical example is when a drug addict patient (patient level) takes peer
advice of not taking the medication (micro-system), and gets access to an illegal antiretroviral
medication market (meso-system), thus, becoming a burden to the health system (exo-system).
Even though these are hypothetical cases they depict the complex, interacting multi-level fac-
tors interweaving with the problem of HAART non-adherence.
One way we analyzed the data was by looking at the number of quotations assigned to a
code or category (G = grounded analysis). This level of analysis gave us the opportunity to
identify the most commonly categories cited by the participants, giving us an approximation of
category saturation. The two most cited barriers for adherence were mental health factors (e.g.
depression, substance abuse, G = 35) and treatment regimen (G = 28) which are also common
barriers to non-adherence. Depression has been identified as one of the most difficult barriers
for medication adherence not only for antiretroviral treatment [13], but for the treatment of
other medical conditions as well [32–33]. A systematic review conducted by Lowther et. Al
(2014) revealed a high point prevalence of depression (33.6%) among people living with HIV
under treatment, thus, increasing the risk of HAART non-adherence [34]. On the other hand,
addiction is another common challenging barrier for optimal antiretroviral adherence [35].
Surprisingly, the third most commonly cited barrier was related to the health system (e.g. med-
ication access, medication co-payment, etc.). This finding warrants further exploration consid-
ering that health system level barriers are not under the patient or even health care provider’s
control. For example, one of the situations cited by participants was that they had to wait for
the medication to be available in the pharmacy, thus, not being able to take their medication.
Another situation was related to health insurance coverage, particularly being unable to cover
medication co-payment. Verification of these stories was out of the scope of the study; how-
ever, future projects should include the perspective of health system administrators or stake-
holders for a more comprehensive exploration of this apparent barrier. Other commonly cited
barriers were related to interpersonal relations (e.g interpersonal conflict, peer pressure,
G = 16) and stigma (e.g. social and internalized, G = 12). Interpersonal relations is a factor that
needs further exploration as it suggests interpersonal conflict or peer pressure as a potential
proxy for non-adherent behavior. This factor should not be explored by itself but as part of a
cluster of other system level factors (personal, macro-system, etc.) that may be potentiating a
synergistic effect for treatment non-adherence. Stigma, on the other hand, has been widely
proven to be a risk factor for HAART non-adherence [33].
One of the goals of this study was to identify HAART adherence facilitators. Different from
adherence barrier, adherence facilitator fell into two system level categories: patient level and
micro-system level facilitators. One reason this might have happened is that the interview
guided participants in barrier categories to talk about their experiences by responding to ques-
tions already contextualized into each system level, while using a single question to ask for
facilitator experiences (refer to Fig 1). A recommendation for future studies is to explore the
existence of other system level facilitators for HAART treatment adherence by incorporating
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other types of questions or interviewing stakeholders or actors representing multiple systems
(e.g. clinicians, administrators, etc.).
Adherence facilitator categories were also subject of grounded analysis. As expected, social
support was the most common cited facilitator for adherence (G = 18) by participants. Other
studies have identified social support as a potential HAART adherence facilitator. For example,
a cohort study conducted by Achieng et. al. (2012) looking for facilitators of retention in care
and antiretroviral treatment adherence in Kenya found that among other factors, participation
in support groups predicted better adherence, and time to treatment failure reduction [36].
One interesting finding about adherence facilitators was the emergence of concerns with health
status (G = 10). These concerns were either imaginary (fear of health deterioration) or real
(actual health deterioration). The fact that some participants waited until their health deterio-
rated to take their medication is like playing at the “Russian roulette”. It represents a very dan-
gerous facilitator because the patient’s life is placed at risk, and it further complicates their care.
Patients relying on this facilitator are probably using the psychological defense mechanism of
denial, making contact with the reality of their diagnosis only when the physical signs of an
opportunistic condition appear. The development of effective strategies to identify and tackle
this dangerous facilitator is recommended.
Questions about primary health care (PHC) interactions were added in this study in an
effort to expand our understanding of PHC recommendation adherence among participants.
Some participants identified patient level barriers, such as fear or shame about certain clinical
procedures and substance abuse, as well as exo-system level barriers, such as transportation
problems. However, we did not find enough evidence of saturation of barriers to PHC recom-
mendations, as most participants stated they followed their primary health care recommenda-
tions. The identified barriers are common in the general populations as well [37–38]. One
potential explanation is that some PHC services provided to the patients were incorporated in
the clinic where recruitment took place, thus, facilitating access and further adherence of such
recommendations.
Strengths and Limitations
One of the strengths of this study is the use of a social ecological model to provide a compre-
hensive view of the HAART non-adherence phenomenon. This approach has been recom-
mended elsewhere [18] and we have received a broader response from participants by using a
comprehensive interview guide. A limitation of the study was having only one recruitment site,
thus limiting the emergence of other system barriers or facilitators attached to other site reali-
ties. Another limitation was the sample size. Although twelve is an acceptable number of par-
ticipants for a descriptive study, it may not be enough to reach saturation of certain
phenomena; such was the case of PHC recommendation barriers.
Conclusion
The results of this study suggest the interconnection of HIV treatment adherence barriers at
various system levels. Future studies on HIV treatment barriers should explore these interac-
tions and investigate the possible synergistic effect on non-adherent behavior. Studying multi-
ple system levels of barriers to HIV treatment adherence can better guide the development of
more comprehensive interventions.
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